A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms
- 25 Downloads
Chromogranin A (CgA) is a valuable biomarker for detection and follow-up of patients with neuroendocrine neoplasms (NENs). However, various comorbidities may influence serum CgA, which decreases its diagnostic accuracy. We aimed to investigate which laboratory parameters are independently associated with increased CgA in real-life setting and to develop a scoring system, which could improve the diagnostic accuracy of CgA in detecting patients with NENs.
This retrospective study included 55 treatment naïve patients with NENs and160 patients with various comorbidities but without NEN (nonNENs). Scoring system (CgA-score) was developed based on z-scores obtained from receiver operating curve analysis for each parameter that was associated with elevated serum CgA in nonNENs.
CgA correlated positively with serum BUN, creatinine, α2-globulin, red-cell distribution width, erythrocyte sedimentation rate, plasma glucose and correlated inversely with hemoglobin, thrombocytes and serum albumin. Serum CgA was also associated with the presence of chronic renal failure, arterial hypertension and diabetes and the use of PPI. In the entire study population, CgA showed an area under the curve of 0.656. Aforementioned parameters were used to develop a CgA-score. In a cohort of patients with CgA-score <12.0 (N = 87), serum CgA >156.5 ng/ml had 77.8% sensitivity and 91.5% specificity for detecting NENs (AUC 0.841, 95% CI 0.713–0.969, P < 0.001). Serum CgA had no diagnostic value in detecting NENs in patients with CgA-score >12.0 (AUC 0.554, 95% CI 0.405–0.702, P = 0.430).
CgA-score encompasses a wide range of comorbidities and represents a promising tool that could improve diagnostic performance of CgA in everyday clinical practice.
KeywordsChromogranin A Comorbidity Diagnostic accuracy Score Neuroendocrine neoplasm
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 11.A. Zissimopoulos, S. Vradelis, M. Konialis, D. Chadolias, A. Bampali, T. Constantinidis et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand. J. Gastroenterol. 49, 942–949 (2014)CrossRefPubMedGoogle Scholar
- 12.P. Gut, A. Czarnywojtek, J. Fischbach, M. Bączyk, K. Ziemnicka, E. Wrotkowska et al. Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch. Med. Sci. Terme. Publ. 12, 1–9 (2016)Google Scholar
- 13.P.R. Bech, R. Ramachandran, W.S. Dhillo, N.M. Martin, S.R. Bloom, Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine and amphetamine-regulated transcript. Clin. Chem. 58, 941–943 (2012).CrossRefPubMedGoogle Scholar
- 25.A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. Eur. J. Endocrinol. 176, 575–582 (2017)CrossRefPubMedGoogle Scholar
- 28.M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157–176 (2012)CrossRefPubMedGoogle Scholar
- 29.C.A. Elisa, Instructions for use Chromogranin A ELISA DEE9000 (2016), Accessed 11 Sep 2017, http://www.ibl-international.com/en/chromogranin-a-elisa
- 34.V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES. Int. J. Cardiol. 168, 5156–5161 (2013)CrossRefPubMedGoogle Scholar
- 41.Healthcare statistics—statistics explained, http://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_statistics. Accessed 11 Sept 2017